FDA Approves FoundationOne®CDx to Identify MSI-H Solid Tumors

Foundation Medicine, Inc. announced that it received approval from the U.S. Food and Drug Administration (FDA) for the FoundationOne®CDx to be used as a companion diagnostic to identify patients with microsatellite instability high (MSI-H) status solid tumors who may be appropriate for treatment with Merck’s Keytruda® (pembrolizumab).

Read the Foundation Medicine announcement.

Posted 2/22/2022